Sanofi has paid big bucks to enter the race to develop a new drug for MS. The drug was developed by Principia Biopharma and crosses the blood-brain barrier making it an attractive candidate not only for MS but for the treatment of other neurological disease.
| less than a minute read
Sanofi Enters the Race to Develop a New Drug for Multiple Sclerosis
Get in touch
Get in touch
Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma. The French Big Pharma is paying $40 million upfront to pick up the preclinical asset, with $765 million more to follow if it passes all the milestones that await.
Get in touch
Get in touch
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-10-08-10-50-28-575-67050e74c71f57809f6d0411.jpg)
Introduction Over the next 2 months, the DLA Piper Life Sciences Blog: Cortex will feature a series of articles providing an insight into...
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-11-19-12-42-49-261-673c87c925126ee9da0a18fc.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-11-05-09-46-46-710-6729e986fa0caa16109ca90f.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Document/2024-11-05-09-42-20-904-A25696_Life_Sciences_Brochure_OctoberEN_Brochure_V2_FINAL_thumbnail_1.png)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-10-31-16-30-14-487-6723b096063041cc69f3284b.jpg)
